Theragnostic Technologies has received an Small Business Innovation Research (SBIR) Phase 1 grant from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/ National Institutes of Health (NIH). The funds will be used to demonstrate the preclinical safety and efficacy of a novel carbon-nanostructure-based X-ray computer tomography (CT) contrast agent (CA) for imaging and
